Saluggia, April 10, 2009 – The Company announces that the annual Corporate Governance Report required pursuant to Article 89 bis of the Issuers' Regulations was filed today at its registered office and at the offices of Borsa Italiana S.p.A. The Report is also available on the Company website (www.diasorin.com).

About Diasorin
Diasorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The Diasorin Group comprises 15 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,000 employees, including 90 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.com

Contacts:

**Investor Relations Officer**
Laura Villa
Diasorin S.p.A.
laura.villa@diasorin.it
+39 0161487532
+39 348 15 11 542

**Press Office**
Carolina Mailander
c.mailander@mailander.it
+39 335 655 56 51
Bruno Caprioli
caprioli@mailander.it
+39 335 590 14 02